http://www.whale.to/vaccines/hib.html

 

HIB VACCINE

"Classen's data and other published data indicates the following vaccines are associated with an increased risk of diabetes (increased risk): hepatitis B (50%), hemophilus (25%), tetanus (20%), diphtheria (9%), pertussis (25%), mumps- rubella (23%).  These findings are supported by a case control study performed in Europe.   The cumulative effect of all these vaccines on diabetes is tremendous."--PRNewswire

The Perilous Haemophilus or is it....pneumonia By Hilary Butler

What is Hib disease?--Greg Beattie

HAEMOPHILUS INFLUENZAE-B VACCINATION PROGRAMS HIGHLY EFFECTIVE, BUT HOW SAFE?

CHILDHOOD IMMUNISATION AND DIABETES MELLITUS

Can Hib Vaccine Cause Asthma?----- Heidi White

http://webpages.netlink.co.nz/~ias/hib.htm

Human data http://vaccines.net/hemophil.htm

Mouse data http://vaccines.net/newpage41.htm

Rat data http://vaccines.net/newpage6.htm

"hib is not a disease but a type of bacteria---defined by lab test....so hard to see if there is any disease decline.......Primary motive was to combat "invasive bacterial infections", but no evidence this has been achieved. 3 major types of "ibi"--hib, pneumococcal, and meningococcal.  ..decline in hib infections appears to have been accompanied by an increase in the other two.... there appears to be no evidence of a decrease in invasive bacterial disease overall.... in aus notifications of meningococcal disease in 1995 was highest since 1979...this rise occurred in parallel with the fall in hib disease, so what savings in illness have there been?....so, there seems to be no demonstration savings in illness in children, on top of this there seems to be an association between dpt vacc and invasive hib disease."--Greg Beattie

"I have published many articles linking vaccines and diabetes. In one study, a clinical trial on the hemophilus vaccine, I showed that the risk of the vaccine exceeds the benefit. This is published by the British medical Journal."--Bart Classen

National Vaccine Injury Compensation Program Vaccine Injury Table http://www.hrsa.dhhs.gov/bhpr/vicp/table.htm#

Schreurs AJ, Nijkamp FP. Bronchial hyperreactivity to histamine induced by Haemophilus influenzae vaccination.
Bronchial hyperreactivity to histamine 4 days following vaccination with the human respiratory pathogen Haemophilus influenzae was tested in two in vivo and one in vitro models. Conscious vaccinated guinea pigs exposed to aerosolized histamine became asphyxial significantly faster than saline-treated controls. Also the bronchoconstriction in anaesthetized guinea pigs as a result of i.v. histamine was significantly potentiated in the H. influenzae pretreated group. Isoprenaline (30 micrograms/kg) partially inhibited the bronchoconstriction. The difference in histamine sensitivity between the two groups however remained. Protection against bronchoconstriction by atropine on the other hand was significantly enhanced in the vaccinated animals. This suggests a hyperreactivity of the parasympathetic, cholinergic pathways as a result of H. influenzae vaccination.
PMID: 6335351, UI: 85118726

Terpstra GK, Raaijmakers JA, Hamelink M, Kreukniet J. Effects of Haemophilus influenzae vaccination on the (para-)sympathic-cyclic nucleotide-histamine axis in rats.Ann Allergy 1979 Jan;42(1):36-40
To determine whether Haemophilus influenzae could be a factor in human atopy its effects were studied on the (para-)Sympathic Cyclic nucleotide-histamine axis in rats. Haemophilus influenzae vaccination induced changes in the cholinergic system compatible with higher cyclic GMP levels and enhanced histamine release. The authors suggest an involvement of the cholinergic system in Haemophilus influenzae vaccination effects. PMID: 216288, UI: 79101862

Basson E, Di Maio M, Stamm D, Cagnin S, Berger C, Floret D.  Arch Pediatr 1996 Apr;3(4):342-4 [Haemophilus influenzae meningitis following vaccination. Consequence or coincidence]?[Article in French] Unite de reanimation pediatrique, hopital Edouard-Herriot, Lyon, France.

BACKGROUND: The introduction of vaccines against Haemophilus influenzae type b (Hib) has had a substantial impact on Hib infections. Their use has established their excellent safety profiles but occasional adverse effects have been reported.
CASE REPORT: A 4 month-old infant was admitted for a severe form of Hib meningitis with septicemia whose first manifestations developed 3 hours after the first immunization with a conjugate vaccine against Hib (PRP-T). The outcome was good without any sequelae.
DISCUSSION: A dramatic decrease in serum antibodies due to antigen-antibody reaction during the first days
after immunization has been reported; this mechanism and some epidemiological data could favor the hypothesis that the vaccine is responsible for the infection, at least the unconjugated vaccines.
CONCLUSION: Any fever occurring in the immediate post-immunization period must alert the possibility of a Hib infection.
http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8762955&form=6&db=m&Dopt=b

Granoff DM, et al.Host and bacterial factors associated with Haemophilus influenzae type b disease in Minnesota children vaccinated with type b polysaccharide vaccine. J Infect Dis. 1989 May;159(5):908-16.  PMID: 2785147; UI: 89215362

Host and bacterial factors were evaluated among 86 Minnesota children with Haemophilus influenzae type b disease detected by active surveillance after introduction of type b polysaccharide vaccine in the state. Children were 2-6 y of age. Thirty-three (38%) had been vaccinated. There was no significant difference between the frequency of low serum concentrations of IgM, IgA, IgG, or IgG2 in the vaccinated and nonvaccinated subjects (13% vs. 8%, P = .5). The presence of the Gm immunoglobulin allotype phenotype (1,3,17;23;5,13,21), previously associated with a lower relative risk of vaccine failure in children from other states, was associated with a fourfold decrease in the relative risk of vaccine failure in Minnesota (P less than .07). Haemophilus isolates from 58 of the children were available for clonal characterization by multilocus electrophoresis and outer membrane protein subtyping. There were no significant differences between the clone distribution of the strains causing disease in vaccinated and nonvaccinated patients, and nearly all disease-producing clones in Minnesota also are known to cause disease in other areas of the country. Thus, vaccine failure in Minnesota is infrequently associated with hypogammaglobulinemia or with infection by unusual clones of a H. influenzae type b. Also, the Gm phenotype associated with protection against vaccine failure in other areas of the USA appears to be protective in Minnesota. PMID: 2785147, UI: 89215362

Granoff et al. (1986) analysed 228 reports of invasive disease due to Hib in vaccinated children submitted to the FDA administration between May 1985 and September 1987. Over 90% of these children were more than 24 months of age, when the vaccine is supposed to be somewhat effective

Granoff et al. (1986)] deals with 55 cases of invasive Hib diseases occurring in Children at least three weeks after vaccination. Meningitis developed in 39 children of whom 3 died and 6 had neurologic after-effects. The level of antibody to Hib in convalescent-phase serum from 31 of the vaccinated children who had Hib disease was significantly lower than that in the serum from 25 patients of similar age (range 17 to 47 months) with the disease who had never received the Hib vaccine.

"Risk factors for invasive Haemophilus influenzae disease among children 2-16 years of age in the vaccine era, Switzerland, 1991-1993" (International Journal of Epidemiology, vol. 25, no. 6, December 1996, pp. 1280-5): "Continued surveillance, and detailed investigation of direct and indirect effects of conjugated vaccines and risk factors…are important." 143 cases with invasive disease were selected, and vaccination status ascertained. "Cases more often than controls reported suffering from asthma and allergies… The observed association between asthma and epiglottitis is novel and deserves further investigation."

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.